Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GlucoStem
- Development stage
- Preclinical
- Lead developer
- Escape Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
GlucoStem is an off-the-shelf, universal cell therapy being developed by Escape Therapeutics for the treatment of Type 1 diabetes. Utilizing the proprietary PluraStem™ embryonic stem cell platform, the therapy consists of allogeneic, immune-evasive pancreatic β cells designed to be transplanted into patients of any HLA type without requiring lifelong immunosuppression. The primary goal of GlucoStem is to restore endogenous insulin production by replacing or supplementing the pancreatic β cells destroyed by autoimmune attack, potentially liberating patients from insulin dependence. The product is currently in the research stage of development.
- Brand names
- GlucoStem
Beyond the preview
Go deeper on GlucoStem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlucoStem.